Calcium Phosphate Product Is Associated with Subclinical Carotid Atherosclerosis in Type 2 Diabetes

J Diabetes Res. 2017:2017:3498368. doi: 10.1155/2017/3498368. Epub 2017 Aug 3.

Abstract

Aims: To assess whether circulating 25-hydroxyvitamin D3 (25OHD) and mineral metabolism-related factors (serum phosphate, calcium, and parathormone) are associated with subclinical carotid atherosclerosis (SCA), defined as the presence of carotid atherosclerotic plaques (main study outcome), in patients with type 2 diabetes mellitus (T2DM) without kidney disease or previous cardiovascular disease.

Methods: We undertook a post hoc analysis of a cross-sectional study in adults with T2DM in whom we evaluated SCA. A total of 303 subjects with T2DM were included. Clinical variables and carotid ultrasound imaging were obtained.

Results: We found no association of 25OHD with the presence of SCA. However, calcium phosphate (CaP; mg2/dL2) product was positively associated with the presence of carotid plaques (ORadj = 1.078; 95% CI: 1.017-1.142). An inverse association was observed between higher levels of 25OHD (≥30 ng/mL versus <20 ng/mL concentrations) and common carotid intima-media thickness (cIMT; mm) (βadj ± SE = -0.055 ± 0.024). We conclude that the CaP product is independently associated with the presence of established subclinical carotid atherosclerosis in patients with T2DM.

MeSH terms

  • Aged
  • Asymptomatic Diseases
  • Calcium Phosphates / blood*
  • Carotid Artery Diseases / blood*
  • Carotid Artery Diseases / etiology
  • Case-Control Studies
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Angiopathies / blood*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood

Substances

  • Calcium Phosphates
  • Vitamin D
  • calcium phosphate
  • 25-hydroxyvitamin D